4//SEC Filing
Ho Tony W 4
Accession 0001209191-20-064857
CIK 0001674416other
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:55 PM ET
Size
25.9 KB
Accession
0001209191-20-064857
Insider Transaction Report
Form 4
Ho Tony W
See Remarks
Transactions
- Exercise/Conversion
Common Shares
2020-12-21$16.90/sh+23,551$398,012→ 57,515 total - Sale
Common Shares
2020-12-21$150.16/sh−1,600$240,256→ 53,315 total - Sale
Common Shares
2020-12-21$149.18/sh−900$134,262→ 54,915 total - Sale
Common Shares
2020-12-21$151.58/sh−1,100$166,738→ 52,215 total - Sale
Common Shares
2020-12-21$148.38/sh−8,400$1,246,392→ 41,915 total - Sale
Common Shares
2020-12-21$149.73/sh−5,000$748,650→ 36,915 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-21−23,551→ 236,449 totalExercise: $16.90Exp: 2027-08-01→ Common Shares (23,551 underlying) - Sale
Common Shares
2020-12-21$148.11/sh−1,700$251,787→ 55,815 total - Sale
Common Shares
2020-12-21$152.41/sh−500$76,205→ 51,715 total - Sale
Common Shares
2020-12-21$147.05/sh−1,400$205,870→ 50,315 total - Sale
Common Shares
2020-12-21$150.61/sh−2,951$444,450→ 33,964 total
Footnotes (12)
- [F1]Includes 217 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.20 to $150.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.44 to $151.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F12]This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% vested on 8/1/2018 and the remaining 75% vest in 36 equal monthly installments on the final day of each succeeding calendar month.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.44 to $148.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.755 to $150.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.04 to $152.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.00 to $147.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.19 to $149.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001713637
Filing Metadata
- Form type
- 4
- Filed
- Dec 21, 7:00 PM ET
- Accepted
- Dec 22, 4:55 PM ET
- Size
- 25.9 KB